Combined business delivers world-leading imaging capabilities to drive improved decision-making from early drug discovery to late-phase clinical development and software for research and drug development, Invicro has announced the acquisition of UK-based Imanova.

Invicro and Imanova will merge all activities to establish the world’s largest provider of translational imaging services and analytics from pre-clinical development through to late-phase clinical trials.

Dr. Jack Hoppin, Invicro’s Co-Founder and CEO said, “Joining forces with the phenomenal research team at Imanova expands our translational, analytic and geographic offering.  Our groups share a common mission of improving research trials through the development and application of quantitative imaging biomarkers. Our combined research teams hold a collective pride in the development of novel offerings in discovery as well as the engineering of scalable, reproducible solutions for deployment in late-phase development.”

Dr. Kevin Cox, Imanova’s CEO said,“Invicro develops innovative analytical approaches for clinical trials, which are highly complementary with our own. Combining Invicro’s and Imanova’s analytics platforms means we have a best-in-class imaging informatics team to help reduce risk in drug development. As a combined enterprise we will be a truly translational quantitative biomarker company, with an expanding late-phase clinical trial offering, able to meet the needs of a growing global market.”